Takara Bio Company Description

Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally.

The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names.

It also provides contract services for regenerative medicine products, such as manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking; and contract services for gene analysis and testing, including sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing.

In addition, the company is involved in developing platform technology for biologics development in areas, such as gene therapy.

The company was incorporated in 2002 and is based in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

Takara Bio Inc.

Country	Japan
Founded	2002
Industry	Biotechnology
Sector	Healthcare
Employees	1,838
CEO	Koichi Nakao

Contact Details

Address: 7-4-38 Nojihigashi Kusatsu, 525-0058 Japan
Phone	81 77 565 6920
Website	takara-bio.com

Stock Details

Ticker Symbol	4974
Exchange	Tokyo Stock Exchange
Fiscal Year	April - March
Reporting Currency	JPY
ISIN Number	JP3460200003
SIC Code	2836

Key Executives

Name	Position
Koichi Nakao	Chief Executive Officer
Yoh Hamaoka	Chief Financial Officer
Takuya Kakemi	Head of Investor Relations